IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis : Episode 14

Opinion

Video

February 25, 2025

Lebrikizumab in Patients With Skin of Color (ADmirable)

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

EP: 1.Heterogenous Presentation Of Atopic Dermatitis

EP: 2.Use of Biopsy and Diagnosing New-Onset AD

EP: 3.Treatment Options in Atopic Dermatitis

EP: 4.Improvement in Standard of Care in Atopic Dermatitis

EP: 5.Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP: 6.Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP: 7.IL-13–Targeting Agents in Atopic dermatitis

EP: 8.Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP: 9.Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP: 10.Switching or Staying Within the Treatment Class

EP: 11.Use of Combination Therapy in Atopic Dermatitis

EP: 12.Safety Data With Biologics in Atopic Dermatitis

EP: 13.Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

EP: 14.Lebrikizumab in Patients With Skin of Color (ADmirable)

Video content above is prompted by the following:

AD is fairly common in patients with skin of color, but we have limited data with AD drugs in these patients.
Please discuss data from other studies, including any real-world data.

Related Videos

After the Smoke: Wildfire Cleanup & Air Quality Concerns with Afif El-Hasan, MD

Atopic Disease Hypersensitivity Reactions Vary by Biologic Type with Valerie Jaroenpuntaruk, MD

5 experts in this video

3 experts are featured in this series.

3 experts are featured in this series.

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.